Robert Petit, Chief Medical Officer and Chief Scientific Officer of OS Therapies Inc, filed a Form 4 on October 30, 2026, disclosing the grant of stock options to purchase 200,000 shares of common stock on October 22, 2026.

Key Highlights

  • Grant date: Options were granted on October 22, 2026, with an expiration date of October 22, 2036.
  • Option size: 200,000 stock options (right to buy) were awarded to Robert Petit.
  • Exercise price: The options carry an exercise price of $1.25 per share.
  • Vesting schedule: Options vest in 12 equal monthly installments on each monthly anniversary of the grant date, subject to continued employment.
  • Plan: The grant was made under the issuer's amended and restated 2023 incentive compensation plan.
  • Resulting ownership: Following the transaction, Petit directly beneficially owns 200,000 derivative securities and 200,000 shares of common stock underlying those options.

Robert Petit Option Grant Details at OS Therapies

According to the Form 4 filed with the SEC on October 30, 2026, Robert Petit, identified in the filing as Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated (NASDAQ:OSTX), received a grant of stock options on October 22, 2026. The options give Petit the right to purchase 200,000 shares of the company's common stock at an exercise price of $1.25 per share.

The filing states that the options were granted "pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan." The options have an expiration date of October 22, 2036. According to the filing, the options vest in 12 equal installments on each monthly anniversary of the grant date, "provided that the reporting person is serving as an employee of the issuer on each applicable vesting date." The price of the derivative security at grant is listed as $0.

The Form 4 indicates that following the reported transaction, Petit directly holds 200,000 stock options and an equivalent number of underlying common shares on a derivative basis. No non-derivative common stock holdings are listed separately in Table I of the filing beyond the column for amount beneficially owned, which shows 200,000 shares directly held.

What Was Disclosed

OS Therapies Inc disclosed a stock option award of 200,000 shares at $1.25 per share to its Chief Medical Officer and Chief Scientific Officer, Robert Petit, granted on October 22, 2026, under the company's amended and restated 2023 incentive compensation plan, vesting over 12 monthly installments.